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TO THE EDITOR
Drug-induced liver injury (DILI) is an important cause of
mortality and morbidity in the general population. Patients
suffering from DILI may present with symptoms ranging
from minor, nonspecific changes in hepatic structure and
function to fulminant hepatic failure or chronic hepatitis.
1
Thiocolchicoside is widely used as a muscle relaxant. The
primary side effects of thiocolchicoside are nausea, somno-
lence, allergy and vasovagal reaction.
2 Epileptic seizures
following thiocolchicoside ingestion have been reported in a
few cases
3, but other systemic side effects, such as
cardiotoxicity, nephrotoxicity or hepatotoxicity, have not
been reported. Here, we report the case of a patient whose
hepatic and cholestatic enzyme levels were elevated during
thiocolchicoside therapy and returned to normal after
thiocolchicoside was discontinued. Resolution of the hepa-
totoxicity was observed after discontinuation of the drug
and the initiation of conservative treatment measures. An
objective causality assessment, based on a Naranjo score
4 of
6, suggests that the liver injury was related to the
thiocolchicoside treatment.
A 58-year-old man was admitted to the emergency clinic
with abdominal discomfort, nausea and a yellowish
discoloration of the sclera. Complete blood count and
hemostasis parameters were normal. The patient’s biochem-
ical test results were as follows: blood urea nitrogen 30 mg/
dl (normal: 0 to 40 mg/dl), creatinine 0.9 mg/dl (normal: 0.6
to 1.3 mg/dl), albumin 3.7 mg/dl (normal: 3.5 to 4.5 mg/dl),
lactic dehydrogenase 320 IU/L (normal: 0 to 125 IU/L), total
bilirubin 3.5 mg/dl (normal: 0.6 to 1.2 mg/dl) with direct
bilirubin 3 mg/dL (normal: 0.2 to 0.4 mg/dl) and indirect
bilirubin 0.4 mg/dl (normal: 0.4 to 0.8 mg/dl), alkaline
phosphatase 280 IU/L (normal: 64 to 160 IU/L), gamma
glutamyl transpeptidase 204 IU/L (normal: 20 to 64 IU/L),
alanine aminotransferase 368 IU/L (normal: 0 to 54 IU/L),
aspartate aminotransferase 346 IU/L (normal: 0 to 34 IU/L),
serum amylase 280 IU/L (normal: 0 to 250 IU/L). The
patient was taking no drugs other than thiocolchicoside and
was not consuming alcohol at the time. Viral serologies
(hepatitis A, B and C; cytomegalovirus; Epstein-Barr;
herpes simplex; and HIV) and all of the tests for
autoantibodies typical of autoimmune liver diseases were
negative. Abdominal ultrasonography and magnetic reso-
nance cholangiopancreatography revealed no pathology.
Thiocolchicoside was discontinued, and liver and chole-
static enzymes began to decrease, but complete normal-
ization of biochemical parameters was not achieved until 12
days later.
DISCUSSION
DILI can be defined as a liver injury induced by drugs
or herbal medicines that leads to liver enzyme abnorm-
alities. The diagnosis of DILI is based on the exclusion of
other possible causes of hepatic dysfunction and on a
close association between drug administration and the
onset of liver disease. Due to methodological difficulties,
the true prevalence of DILI is not known, but an
occurrence of approximately 14 cases per 100,000 popula-
tion per year has been reported. Antibiotics, analgesics
and NSAIDs are the most common causes of DILI.
1
Thiocolchicoside is a semi-synthetic derivative of colchico-
side that exhibits selective affinity for gamma-aminobu-
tyric acid and glycinergic receptors.
5 Thiocolchicoside is
used as a muscle relaxant in the treatment of symptomatic
spasms and contractures in muscular, rheumatic and
neurologic disorders. Adverse events from the use of
thiocolchicoside are rarely reported. The main side effects
of thiocolchicoside are nausea, somnolence, asthenia,
allergy and vasovagal reactions.
2,5 Colchicine, an analog
of colchicoside, is also a commonly used drug, especially
for rheumatic diseases. Crocenzi et al.
6 demonstrated that
in experimental models, colchicine-induced hepatotoxicity
depended on the magnitude and composition of the bile
salt flux traversing the liver. Atas ¸ et al.
7 reported the
cases of four children who presented with gastrointestinal
symptoms, hepatotoxicity, cardiotoxicity and bone mar-
row suppression after colchicine poisoning. However, no
cases of hepatotoxicity resulting from therapeutic doses of
either thiocolchicoside or colchicine have been reported.
In our patient, serum AST and ALT levels were increased
when oral thiocolchicoside was administered at 8 mg/
day. Two weeks after discontinuing thiocolchicoside
therapy, lever enzymes had decreased to normal levels.
Because of the increase in the serum aminotransferase
levels upon the initiation of thiocolchicoside and their
return to normal levels when the drug was discontinued,
the negative serology for acute viral infection, the
negative tests for autoantibody markers and the exclusion
of other drugs or potentially hepatotoxic agents, we
believe that thiocolchicoside at therapeutic doses may
cause liver injury in some patients. To our knowledge,
this is first case of thiocolchicoside-induced hepatotoxicity
that has been reported. Although this toxicity occurs only
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521infrequently, thiocolchicoside should be considered to be
a rare hepatotoxic agent in clinical practice.
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